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The cardiopulmonary exercise test (CPET) is an established tool to
assess prognosis in patients with heart failure (HF) [1–3]. However,
little is known about the prognostic value of CPET in patients with HF
due to Chagas disease. We assessed the performance of functional
variables from 1) the CPET; 2) echocardiograms; and 3) the 6-min
walk test (6MWT) in predicting quality of life and long-termmortality
among patients with HF due to Chagas disease.
We studied 55 patients with HF due to Chagas disease with left
ventricular dysfunction (ejection fraction [EF] b45%) and symptoms
who were identiﬁed from participants in 2 randomized clinical trials
[4] and followed for all-cause mortality. A detailed description of the
study procedures was previously published [5]. This study was
approved by the institutional review board of the Santa Izabel
Hospital, Bahia, Brazil. All patients gave informed consent to
participate in the trials.
Continuous variables were described as mean ± SD. The Student t
test and Chi-square test were used as appropriate. Correlations with
quality of life were assessed by univariable and multivariable linear
regression analyses (backward stepwise protocol). C statistic and
receiver operating characteristic (ROC) curves were used to determine
the best thresholds for mortality prediction. Kaplan–Meier survival
curves were constructed based on these thresholds, and multivariable
Cox proportional hazard analysis (backward stepwise protocol) was
used to determine associations with survival. A p value b0.05 was
considered signiﬁcant.
There was no loss to follow-up, and the mean follow-up was 32 ±
19 months. Patients were distributed among New York Heart
Association classes II to IV as follows: class II, 41 patients (74%);
class III, 12 patients (22%); and class IV, 2 patients (4%). Sinus rhythm
was present in 40 patients (73%), 6 (11%) patients were on atrial
ﬁbrillation, and 9 (16%) had a pacemaker. The mean heart rate was
68 ± 8 bpm.
In general, patients were well treated for HF: 89% took an
angiotensin-converting enzyme inhibitor or angiotensin receptor
blocker, 62% used beta-blockers, 86% a diuretic, and 74% an
aldosterone blocker. A complete description of the baseline popula-
tion characteristics was previously published [5].
By echocardiogram, mean EF was 27.6% ± 6.6%, and mean left
atrial diameter was 44 ± 7 mm. The mean distance during the 6MWT
was 399 ± 102 m, and the mean Chagas score [6] was 13 ± 2.5, which
is compatible with the higher risk group for this score. The CPET
results showed a mean peak oxygen consumption (VO2) of 17.3 ±
6.2 mL/kg/min, an exchange ratio of 1.08 ± 0.18, a ventilation
efﬁciency (VE/VCO2) slope of 36 ± 10, an O2 pulse of 9.4 ± 3.5 mL/
beat, and an oxygen uptake efﬁciency slope of 0.66 ± 0.27 L/min.
Mean Minnesota Living with Heart Failure Questionnaire (MLHFQ)
score was 38 ± 18. There were signiﬁcant correlations between better
qualityof life andhigherpeakVO2 (r =−0.301, p = 0.02), higher6MWT
distance (r =−0.375, p = 0.007), and higher EF (r =−0.282,
p = 0.03). Together, these variables explained 30% of the variation
in the MLHFQ. The 6MWT distance was the only factor independently
associated with higher MLHFQ score. Each 10-m increase in the distance
walked in the 6MWTwas associatedwith a reduction of 0.7 points in the
MLHFQ score.
At the ﬁnal follow-up, 39 patients (71%) were dead. Non-survivors
had signiﬁcantly lower EF and higher Chagas scores. From the CPET,
only peak VO2 and VE/VCO2 slopewere signiﬁcantly different between
survivors and non-survivors (Table 1).
The C statistics for the relationship between peak VO2 and VE/VCO2
slope and mortality were 0.70 (95% conﬁdence interval [CI]: 0.55 to
0.85, p = 0.02) and 0.73 (95% CI: 0.59 to 0.87, p = 0.007),
respectively. Based on ROC curve analysis, the best cut point for
mortality discrimination was ≤18 mL/kg/min for peak VO2
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Table 1
Functional capacity and quality of life in survivors and non-survivors.
Survivors Non-survivors p value
N 16 39
Age (yrs) 51 ± 9 51 ± 9 0.96
Peak VO2 (mL/kg/min) 20 ± 6 16.2 ± 6 0.03
VO2 at AT (mL/kg/min) 12.3 ± 3 11.3 ± 3.6 0.32
VE/VCO2 slope 30 ± 7 38 ± 11 0.01
OUES (L/min) 0.71 ± 0.22 0.65 ± 0.28 0.47
O2 pulse (mL/beat) 10 ± 4.4 8.8 ± 3.0 0.10
HRR1 b16 53% 65% 0.43
EF (%) 30 ± 6 26 ± 6 0.04
LA diameter (mm) 43 ± 6 45 ± 7 0.39
LVESD (mm) 56 ± 8 61 ± 9 0.49
LVEDD (mm) 66 ± 7 69 ± 9 0.14
6MWT (m) 443 ± 123 382 ± 89 0.05
MLHFQ 32 ± 19 41 ± 17 0.11
NSVT 68% 82% 0.27
Serum sodium (mg/dL) 138 ± 4 138 ± 4 0.81
Chagas score 11 ± 2 14 ± 2 0.01
Results are presented as mean ± SD, except for NSVT and HRR1, which are presented as
proportions.
AT, anaerobic threshold; EF, ejection fraction; HRR1, heart rate recovery at theﬁrstminute;
LA, left atrial; LVEDD, left ventricle end diastolic diameter; LVESD, left ventricle end systolic
diameter; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NSVT, non-
sustained ventricular tachycardia; O2, oxygen; OUES, oxygen uptake exercise slope;
6MWT, 6-min walk test; VCO2, carbon dioxide production; VE, ventilation; VO2, oxygen
consumption.
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(sensitivity 74% and speciﬁcity 69%) and ≥32.5 for VE/VCO2 slope
(sensitivity 72% and speciﬁcity 69%).
Fig. 1 shows the Kaplan–Meier curves for mortality according
to the thresholds of peak VO2 and VE/VCO2. Patients with peak
VO2 ≤18 mL/kg/min had a mean survival of 29 ± 3 months versus
46 ± 5months for those with peak VO2 N18 mL/kg/min (p= 0.013).
Patients with a VE/VCO2 slope ≥32.5 had a mean survival of 28 ±
3months versus 47 ± 5months for those with a VE/VCO2 slope b32.5
(p= 0.006).
After adjustment for age, EF, and Chagas score, peak VO2 was
no longer signiﬁcantly associated with mortality (adjusted hazard
ratio [HR]: 0.97, 95% CI: 0.91 to 1.04, p = 0.44); VE/VCO2 slope
remained an independent predictor of long-term mortality (adjusted
HR: 2.80, 95% CI: 1.30 to 5.80, p = 0.001, for those with VE/VCO2 slope
≥32.5; or adjusted HR: 1.04, 95% CI: 1.01 to 1.07, p = 0.01, per unit
increase in VE/VCO2 slope). Chagas score was also an independent
predictor of mortality (adjusted HR: 1.28, 95% CI: 1.10 to 1.48,
p = 0.001).
We demonstrated that better performance in the 6MWT was
independently related to better quality of life as assessed by the
MLHFQ. Also, we showed that higher VE/VCO2 slope was the only CPET
variable associated with greater long-termmortality in this population.
Finally, we observed that the thresholds that discriminated mortality
among Chagas patients with HF were less extreme than those used for
assessmentof patientswithHFof other etiologies [7,8]. Thisﬁndingmay
reﬂect amore severe disease stage despite less functional limitation and
the possible need for earlier intervention amongpatientswithHFdue to
Chagas.
In conclusion, among patients with HF due to Chagas disease,
longer distance walked in 6 min was independently associated with
better quality of life. VE/VCO2 slope was an independent predictor of
long-termmortality. If validated, our results may have implications for
assessment of prognosis and clinical decisionmaking for patients with
HF due to Chagas disease.
The authors of this manuscript have certiﬁed that they comply
with the Principles of Ethical Publishing in the International Journal of
Cardiology.
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Fig. 1. Kaplan–Meiermortality curves for peakVO2 (A) andVE/VCO2 slope (B) according to
ROC-derived thresholds.
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